| Project/Area Number |
16F16420
|
|---|
| Research Category |
Grant-in-Aid for JSPS Fellows
|
| Allocation Type | Single-year Grants |
|---|
| Section | 外国 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
井本 浩 鹿児島大学, 医歯学域医学系, 教授 (60274461)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ARYAL BIBEK 鹿児島大学, 医学部, 外国人特別研究員
|
|---|
| Project Period (FY) |
2016-11-07 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2017: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2016: ¥500,000 (Direct Cost: ¥500,000)
|
|---|
| Keywords | Platelet / VEGF-A / Bevacizumab / Pegapyinib / Sunitinib / Colorectal Cancer / Angiogenesis / Pegaptinib |
|---|
| Outline of Annual Research Achievements |
As proposed in our proposal, we have examined two agents in ex vivo and in vitro models (Bevacizumab and Pegaptinib), and only Bevacizumab in human study. We recruited patients diagnosed with advanced colorectal cancer, and isolated the platelets at different interval.
We observed a dismal effect of bevacizumab on the concentrations of intra-platelet VEGF-A. The human study results correspond with our ex vivo and in vitro experiments. Compared to serum and plasma, the intra-platelet VEGF-A concentrations remained nearly unchanged. We have also monitored the kinetics of different isoforms of VEGF-A in platelets obtained from the patients before and after Bevacizumab administration. To increase the number in human study, we have recently modified the protocol of patient recruitment.
|
| Research Progress Status |
29年度が最終年度であるため、記入しない。
|
| Strategy for Future Research Activity |
29年度が最終年度であるため、記入しない。
|
